Rapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques
作者机构：State Key Laboratory for Zoonotic DiseasesKey Laboratory for Zoonosis Research of the Ministry of EducationInstitute of Zoonosisand College of Veterinary MedicineJilin University130062 ChangchunChina Institute of Medical BiologyChinese Academy of Medicine Sciences&Peking Union Medical CollegeYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases650118 KunmingChina Walvax Biotechnology Co.Ltd650106 KunmingChina College of Animal Science and TechnologyInner Mongolia University for Nationalities028000 TongliaoChina Changchun Veterinary Research InstituteChinese Academy of Agricultural SciencesChangchunChina Yuxi JOZO Biotechnology co.LTD653199 YuxiChina National Medical Center for Major Public Health EventsState Key Laboratory for Zoonotic DiseasesDepartment and Institute of Infectious DiseaseTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2022年第7卷第8期
页 面：2687-2689页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学]
基 金：supported in part by the National Key Research and Development Program of China(2021YFC2600200)
主 题：quantities restricted treatment
摘 要：Dear Editor,The unprecedented COVID-19 pandemic caused by SARS-CoV-2 remains ongoing,but there is a lack of fully effective *** plasma-derived hyperimmune globulins have been a safe and effective treatment but restricted by the difficulties in obtaining sufficient plasma with high antibody titers from a large number of recovered *** antibodies,particularly equine antibodies,have been widely used for decades as the therapeutics against some viral infections or as antivenoms.1 Equine antibodies could be rapidly developed and manufactured into therapeutic antibodies in large quantities under WHO standardized *** we explored the development of equine antibody-derived F(ab′)2 as an option to treat COVID-19 by targeting the receptor-binding domain(RBD)of the viral spike protein that is essential for the viral entry into the host cells.2 We observed excellent neutralization titers of the F(ab′)2 in vitro and high potency against SARS-CoV-2 infection in the nonhuman primate rhesus macaques.
维普期刊数据库